Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.

Date publication

mai 2022

Journal

Tumori

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BASTOGNE Thierry , Dr MIRJOLET Céline

Tous les auteurs :
Deneuve S, Bastogne T, Duclos M, Mirjolet C, Bois P, Bachmann P, Nokovitch L, Roux PE, Girodet D, Poupart M, Zrounba P, Claude L, Ferella L, Iacovelli NA, Foray N, Rancati T, Pereira S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35578746

Résumé

Radiotherapy (RT) against head and neck squamous cell carcinomas (HNSCC) may lead to severe toxicity in 30-40% of patients. The normal tissue complication probability (NTCP) models, based on dosimetric data refined the normal tissue dose/volume tolerance guidelines. In parallel, the radiation-induced nucleoshuttling (RIANS) of the Ataxia-Telangiectasia Mutated protein (pATM) is a predictive approach of individual intrinsic radiosensitivity. Here, we combined NTCP with RADIODTECT©, a blood assay derived from the RIANS model, to predict RT toxicity in HNSCC patients.

Mots clés

Head and neck squamous cell carcinomas, biological marker, normal tissue complication probability, pATM, predictive models, radiation-induced toxicity

Référence

Tumori. 2022 05 16;:3008916221078061